中文摘要：

通过测量不同低浓度血小板衍生生长因子-BB（PDGF-BB）水溶液的表面增强拉曼光谱（SERS）,可以检测到质量分数低至10-8的PDGF-BB水溶液在拉曼频移为1509cm-1处的拉曼特征峰。通过检测行皮冠状动脉介入治疗术（PCI）患者（动脉粥样硬化程度较高）术前尿液样本与未行PCI患者（动脉粥样硬化程度较低）尿液样本SERS,并结合PDGF-BB的1509cm-1处拉曼特征峰可以发现,行PCI患者尿液样本的SERS中可以检测到PDGF-BB的拉曼特征峰,即PDGF-BB在尿液中的浓度与动脉粥样硬化程度相关。结果表明,SERS技术可以检测到极低浓度PDGF-BB水溶液的拉曼特征峰,尿液的SERS可以成为判断冠心病患者是否需要进行PCI的重要依据,因此SERS技术有望成为一种无损检测与筛查冠心病的临床诊断工具。

英文摘要：

By measuring the surface-enhanced Raman spectra （SERS） of various low concentrations of plateletderived growth factor-BB （PDGF-BB） aqueous solution, the Raman characteristic peak at Raman shift of 1509 cm^-1 can be detected for PDGF-BB aqueous solution with mass fraction as low as 10-8. By detecting SERS of urine samples of the preoperative patient who has higher degree of atherosclerosis and is treated with percutaneous coronary intervention （PCI） and the patient who has lower degree of atherosclerosis and is not treated with PCI, as well as the Raman characteristic peak of PDGF-BB at Raman shift of 1509 cm-~ , we find that the peak at 1509 cm-~ can be detected on the SERS of the patient with PCI, which reveals that the concentration of PDGF-BB in urine is correlative with the degree of atherosclerosis. The results show that the low concentration of aqueous solution of PDGF-BB can be detected by SERS technology, and the SERS of urine sample can he used to determine whether the patients with coronary heart disease need to have PCI. Hence, the technology will he a clinical diagnostic tool for non-destructive testing and screening coronary heart disease.